A partnering opportunity is now open for DD01, a promising investigational therapy developed by D&D Pharmatech for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). As of April 2nd, the company has announced the successful grant of a key patent in Australia, further strengthening the global intellectual property position of this candidate.

DD01 is a long-acting dual GLP-1/glucagon receptor agonist with demonstrated potential in reducing liver fat and addressing the root causes of MASH. In March 2023, DD01 received Fast Track Designation from the U.S. FDA, highlighting its potential to meet significant unmet medical needs.

The program is currently in a Phase 2 clinical trial in the U.S., where patients receive 12 weeks of treatment. The primary endpoint is liver fat reduction, measured by MRI-PDFF. Patient enrollment was completed in January, and topline data is expected by June 2024.

In a previous Phase 1 study, DD01 showed highly encouraging results: 75% of patients in the 40mg cohort achieved statistically significant reductions in hepatic fat after just 4 weeks. The current trial is also assessing histological outcomes—including MASH resolution and fibrosis improvement—over a 48-week extension period, with results expected in early 2026.

D&D Pharmatech anticipates that the newly secured Australian patent will play a pivotal role in the global partnering process. If the upcoming Phase 2 data readout is favorable, the company aims to pursue a licensing deal within the year.

With strong clinical momentum, a differentiated dual agonist mechanism, and expanding global IP coverage, DD01 is now open for strategic partnership discussions.

Interested parties are encouraged to engage for more information and partnership opportunities.